Zurück zur Übersicht
| OncoTargets and therapy. 2018 Nov 30. doi: 10.2147/OTT.S161506. pii: ott-11-8565. pmc: PMC6292388 |
| Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung. |
| Lu S1, Li W2, Zhou C3, Hu CP4, Qin S5, Cheng G6, Feng J7, Wang J8, Cseh A9, Peil B10, Gibson N11, Ehrnrooth E12, Zhang L13 |
 Author information
|
|
Abstract BACKGROUND: The global Phase III LUX-Lung 8 trial (ClinicalTrials.gov: NCT01523587) identified significant improvements in progression-free survival (PFS), overall survival (OS), and patient-reported outcomes (PROs) with second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung. MATERIALS AND METHODS: We conducted a post hoc analysis of data for patients in LUX-Lung 8 from mainland China (n=67). Compared with erlotinib, afatinib reduced the risk of disease progression or death (PFS) in the Chinese subgroup by 30% (HR=0.70; 95% CI: 0.38-1.27). RESULTS: The risk of death was reduced by 31% (HR=0.69; 95% CI: 0.39-1.21). The proportion of Chinese patients with improvements in PROs also favored afatinib vs erlotinib (global health status/quality of life [QoL], 52.8% vs 29.6%, =0.072; dyspnea, 47% vs 26%, =0.091; "dyspnea walked", 44% vs 15%, =0.017; QoL rate, 53% vs 26%, =0.037). DISCUSSION: While this analysis was not powered to demonstrate differences compared to the overall trial population (OTP), and there were some differences in baseline characteristics (eg, the proportion of patients aged ≥65 years old), the benefits of afatinib treatment in Chinese patients with SCC of the lung appeared to be at least comparable to that observed in LUX-Lung 8. As with the OTP, the most common adverse events (AEs) with afatinib in the Chinese subgroup were diarrhea and rash/acne, and the incidence and type of the most frequently occurring AEs were similar. CONCLUSION: The results suggest that afatinib represents a feasible treatment option for Chinese patients with advanced SCC of the lung following progression on platinum-based chemotherapy. |
|
KEYWORDS: Chinese patients, NSCLC, Phase III, afatinib, second-line, squamous cell carcinoma |
|
Publikations ID: 30573970 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
